Asahi Kasei Corporation

ASAA.F·Frankfurt·Industrials
Compare
9.03+0.10 (+1.16%)today
As of Oct 20, 8:15 AM CEST · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close8.93
Open8.77
Day range8.779.03
52-week range6.5510.24
Off day high0.00%
Off 52-week high−11.80%
Volume1.00
Avg. volume (3M)38.00
Market cap12.04B
EPS (TTM)0.7900
Forward P/E—
P/E ratio (TTM)11.43
Dividend yield2.78% (0.2500)
Beta (5Y)0.66
Shares outstanding1.33B
Short interest—
Earnings dateNov 5, 2026
Analyst target—
Profit margin6.10%

Against its peers

Compare in full ›
ASAA.F 7490.T 4204.T 3106.T 5706.T 6971.T
Market cap 12.04B 14.63B 1.03T 184.05B 1.30T 4.50T
P/E (TTM) 11.4 4.0 14.2 16.8 11.4 34.6
Forward P/E — — 13.2 — 3.8 39.7
Price/book 1.0 0.6 1.2 1.4 3.1 1.4
Dividend yield 2.78% 1.00% 3.21% 2.85% 1.28% 1.59%
1-year change +31.80% +73.97% −8.09% +60.82% +59.45% +65.72%
Today +1.16% 0.00% +0.22% +1.03% +3.77% +1.05%

The closest companies by business and industry (Conglomerates). Prices may be delayed up to 20 min.

Latest news

All ASAA.F news ›
The Globe and Mail·Negative

Goldman Sachs downgrades Asahi Kasei (AHKSF) to a Hold

The Globe and Mail Goldman Sachs analyst downgraded Asahi Kasei to a Hold on October 8 and set a price target of Yen2,010.00. The company’s shares closed last Thursday at Yen1,650.50. The word on The Street in general, suggests a Moderate…

pharmaphorum·Positive

Aicuris acquisition delivers new drug for Asahi Kasei

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex virus (HSV) drug at the heart of the deal. The oral drug, called Hovilpri (pritelivir), has been cleared for…

From articles in the 4Search news index.

In the news

13mentions in 30 days
13with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.